Himalaya Therapeutics

What Himalaya Therapeutics does

Himalaya Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California, with operating subsidiaries in the Cayman Islands, Hong Kong, and Shanghai. It is the sole Greater China licensee of BioAtla Inc.'s Conditionally Active Biologics (CAB) technology — a proprietary antibody engineering platform protected by more than 500 issued and pending patents — which produces antibodies that selectively bind to tumor cells within the acidic tumor microenvironment while remaining inactive in normal tissues, thereby widening the therapeutic window. The company's pipeline comprises three lead candidates: Mecbotamab Vedotin (HTBA3011), a CAB-AXL antibody-drug conjugate in Phase 2 for NSCLC and sarcomas; Ozuriftamab Vedotin (HTBA3021), a CAB-ROR2 ADC in Phase 2 for NSCLC, melanoma, and SCCHN; and CAB-CTLA-4 (HTBA3071), a conditionally active anti-CTLA-4 antibody in Phase 1 co-developed with BeiGene for Greater China.

The business model is a regional licensing and co-development construct. Himalaya acquires CAB-based product candidates developed globally by BioAtla and advances them through clinical trials and regulatory approval within the Greater China territory (mainland China, Hong Kong, and Taiwan), with four IND applications submitted to China's NMPA/CDE in October 2021 and interim Phase 2 efficacy data reported in 2022. Revenue is not yet generated; future income is expected from pharmaceutical product sales upon NMPA approval and from licensing/royalty arrangements such as the BeiGene co-development agreement for the CTLA-4 program. The go-to-market motion is enterprise field sales to hospitals and cancer treatment centers in Greater China, supported by clinical trial site networks, scientific conferences, and regulatory engagement with Chinese authorities. The firm serves oncology patients with solid tumors — particularly those who have failed standard PD-1/L1, EGFR, or ALK inhibitor therapies — where the CAB platform's tumor-selective activation addresses the central limitation of off-target toxicity in traditional antibody therapeutics.

Name

Himalaya Therapeutics

Legal name

Himalaya Therapeutics

Website

https://himalayatherapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Himalaya Therapeutics is a clinical-stage biopharmaceutical company developing CAB (Conditionally Active Biologics) antibody therapeutics for solid tumor cancers, operating as the sole Greater China licensee of BioAtla's CAB technology platform.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Oncology antibody therapeutics
• Conditionally active biologics
• Antibody drug conjugates
• Clinical-stage biopharmaceuticals
• Solid tumor treatment

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue expected from commercialization of CAB-based antibody therapeutics for cancer treatment in Greater China upon regulatory approval.
2. Licensing and Co-development Agreements: Partnership with BeiGene for CAB CTLA-4 antibody (BA3071) development, manufacturing and commercialization in Greater China. The company operates as licensee of CAB technology for Greater China region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Himalaya Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing antibody therapeutics based on its Conditionally Active Biologics (CAB) technology platform for the treatment of solid tumor cancers in Greater China. Its lead candidates are antibody-drug conjugates targeting AXL (HTBA3011/Mecbotamab Vedotin), ROR2 (HTBA3021/Ozuriftamab Vedotin), and a conditionally active CTLA-4 antibody (HTBA3071), all in clinical trials for NSCLC, sarcomas, melanoma, and other solid tumors.

Product overview

Himalaya Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel antibody therapeutics based on its CAB (Conditionally Active Biologics) technology platform. The company's pipeline includes three lead product candidates: Mecbotamab Vedotin (HTBA3011), a CAB-AXL antibody-drug conjugate for NSCLC and sarcomas; Ozuriftamab Vedotin (HTBA3021), a CAB-ROR2 antibody-drug conjugate for NSCLC, melanoma, and SCCHN; and CAB-CTLA-4 (HTBA3071), a CTLA-4 targeting antibody developed with BeiGene. All candidates are designed to selectively target tumor cells while sparing normal tissues, offering improved safety and efficacy compared to traditional antibodies.

Differentiator

Problem solved

Functional benefit

Products and services

• Mecbotamab Vedotin (HTBA3011) A Conditionally Active Biologics antibody-drug conjugate (CAB-AXL-ADC) targeting the AXL protein expressed on tumor cells, in Phase 2 clinical trials for NSCLC and sarcomas (soft tissue and bone). Being developed by Himalaya as the sole Greater China licensee of BioAtla's CAB technology.
• Ozuriftamab Vedotin (HTBA3021) A Conditionally Active Biologics antibody-drug conjugate (CAB-ROR2-ADC) targeting the ROR2 protein expressed on tumor cells, in Phase 2 clinical trials for NSCLC, melanoma, and squamous cell carcinoma of the head and neck (SCCHN).
• CAB-CTLA-4 (HTBA3071) A conditionally active anti-CTLA-4 antibody candidate being co-developed with BeiGene Ltd. for Greater China, currently in Phase 1 clinical trials for solid tumors.

Quantifiable outcome

• 50% ORR in NSCLC monotherapy non-squamous group (4 of 8 patients with PR)
• +4 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• BeiGene Ltd.coreStrategic or Co-development Partner · 26 April 2021Co-development and collaboration agreement for investigational CAB CTLA-4 antibody (BA3071/HTBA3071) with BeiGene for development, manufacturing and commercialization in Greater China.
• BioAtla Inc. (NASDAQ: BCAB)coreTechnology or IntegrationBioAtla is the pioneer of CAB technology. Himalaya is the sole Greater China licensee of CAB technology-derived product candidates. BioAtla conducts global clinical trials outside China while Himalaya advances programs within Greater China. The partnership includes BA3011 (CAB-AXL-ADC) and BA3021 (CAB-ROR2-ADC) programs.
• DeltaMedminorImplementation/ SI/ Consulting PartnerLeading Chinese niche CRO specializing in pharmacovigilance, medical monitoring, medical writing, phase I study and regulatory & clinical development strategy. Founded by Dr. Howe Li, Himalaya's CMO.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioAtla: BioAtla (NASDAQ: BCAB) is the developer and licensor of the CAB platform technology that Himalaya uses; it conducts global clinical trials outside Greater China while Himalaya holds China rights. Directly comparable given shared platform, identical product candidates (BA3011/BA3021/BA3071), and overlapping pipeline strategy.
• Adagene: Adagene (NASDAQ: ADAG) develops conditionally active antibodies using its SAFEbody and POWERbody platforms, targeting the same therapeutic window expansion concept as Himalaya's CAB. Both companies are clinical-stage antibody engineering platforms focused on oncology with similar differentiation narratives.
• Innovent Biologics: Innovent (HKEX: 1801) is a leading Chinese biotech with multiple approved oncology biologics (PD-1, biosimilars) and a pipeline including ADCs (e.g., IBI354) targeting similar indications to Himalaya's NSCLC focus. Comparable Chinese antibody/ADC developer competing for similar oncology market.
• Junshi Biosciences: Junshi (HKEX: 1877; SHA: 688180) is a Chinese biotech with approved PD-1 (Toripalimab) and expanding ADC pipeline targeting NSCLC and other solid tumors. Comparable as a Chinese clinical-to-commercial oncology antibody developer.
• Akeso: Akeso (HKEX: 9926) develops novel antibodies including bispecifics and ADCs for oncology indications including NSCLC. Comparable Chinese antibody-focused oncology biotech with similar pipeline depth and clinical-stage profile.
• Cstone Pharmaceuticals: Cstone (HKEX: 2616) is a clinical-stage Chinese oncology biotech with PD-1 and antibody programs targeting NSCLC and other solid tumors. Comparable scale and stage as Himalaya within the Chinese oncology development landscape.
• RemeGen: RemeGen (HKEX: 9995; SHA: 688331) is a Chinese biotech with approved ADCs (Disitamab Vedotin) and a deep oncology antibody pipeline including HER2 and other ADC targets. Comparable Chinese clinical-to-commercial ADC developer.

Broad incumbents

• BeiGene: BeiGene (NASDAQ: BGNE) is Himalaya's co-development partner for HTBA3071 and a leading Chinese oncology biotech with approved assets (Brukinsa, Tislelizumab). Comparable as a Chinese oncology antibody developer but operates at much greater scale and commercial breadth.
• Daiichi Sankyo: Daiichi Sankyo is the global ADC leader with Enhertu and Datroway (DXd-ADC platform) approved for NSCLC, breast cancer, and other tumors. Comparable as a major ADC player targeting overlapping indications; sets the competitive benchmark CAB-ADCs must beat.
• AstraZeneca: AstraZeneca co-develops and commercializes Enhertu/Datroway with Daiichi Sankyo and has a broad ADC portfolio across NSCLC and other tumors. Comparable as a major pharma incumbent in the ADC space where Himalaya's CAB-ADCs would need to compete.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Himalaya Therapeutics